Moderna, Inc.MRNA

Healthcare
Neutral

ASignal's systematic analysis rates MRNA as Neutral. Moderna, Inc. has a market cap of $21.85B, a -143.6% net margin, and 260.2% year-over-year revenue growth.

Reflects the latest available analysis · analyzed Aug 1, 2026

The case on MRNA

Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.

Bull case
  • Strong revenue growth (260.2% YoY)
  • High cash position ($5.21B) with low debt-to-equity (0.18x)
  • Current ratio of 2.41x indicates solid short-term financial health
  • RSI at 17.85 — deeply oversold, potential for mean reversion
VS
Bear case
  • Negative free cash flow ($-20M) and negative operating cash flow ($-1.47B)
  • Negative margins across gross, operating, and net levels
  • Negative return on equity (-36.56%) and return on assets (-13.09%)
  • MACD below signal line with negative histogram, indicating bearish momentum
  • Price below both SMA20 and SMA50, signaling downtrend
  • No Reddit mentions, suggesting low retail investor interest or engagement

Key facts

Sector
Healthcare
Market cap
$21.85B
Gross margin
-69.9%
Net margin
-143.6%
Rev growth YoY
260.2%
Price (Jul 30, 2026)
$55.08

Peers

Clustered with MRNA by analysis-profile similarity.

Subscriber-only

See the full verdict on MRNA

ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.

How ASignal analyzes MRNA

Most investors never get a second opinion, let alone several. ASignal runs MRNA past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.

The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.

Moderna, Inc. (MRNA) Stock Analysis - ASignal rates it Neutral